What makes the scored, fractionated formulation of CD/LD different from other tablets and what group of patients should be considered appropriate candidates for treatment with this titratable treatment for PD?

What makes the scored, fractionated formulation of CD/LD different from other tablets and what group of patients should be considered appropriate candidates for treatment with this titratable treatment for PD?

What makes the scored, fractionated formulation of CD/LD different from other tablets and what group of patients should be considered appropriate candidates for treatment with this titratable treatment for PD?


Created by

CMEducation Resources iQ&A Parkinson’s Disease (PD) Medical Intelligence Zone

Related Presenters

John Morgan, MD, PhD

John Morgan, MD, PhD

Professor and DirectorMovement & Memory Disorder ProgramsDepartment of NeurologyMedical College of GeorgiaAugusta UniversityAugusta, Georgia